On July 13, state Food and Drug Administration announced that the pantoprazole sodium enteric-coated tablet, commissioned by Hangzhou Kangenbei Pharmaceutical Co., LTD., was approved for production by Duzheng Biological for BE study (Hunan Occupational Disease Prevention and Control Institute for clinical practice). This is also the fifth project approved by Duzheng Biology since July 22!

Pantoprazole is a commonly used drug for the treatment of peptic ulcer and other diseases, and belongs to benzimidazoles proton pump inhibitors (PPI). Its action and mechanism are the same as prileprazole, but its binding selectivity with proton pump is higher and more stable, which is generally believed to be stronger than prileprazole. In 2019, the domestic sales reached 5.78 billion yuan. 

（数据来源：IMS 中国）